How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →

NiKang Therapeutics® Presents Discovery of NKT3964, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2 PROTAC Degrader for Cancer Therapy, at the EORTC-NCI-AACR Symposium 2024

calendar_today October 24, 2024 person Elizabeth Aspinall domain nikang-therapeutics

See the press release on Business Wire